A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of its Precision Cell Therapies Using its Proprietary Tmod(TM) Technology Platform Portfolio News / By Karina Tin A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of its Precision Cell Therapies Using its Proprietary Tmod(TM) Technology Platform Read More »
Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics Portfolio News / By Karina Tin Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics Read More »
RAPT Therapeutics Announces $150 Million Private Placement Portfolio News / By Karina Tin RAPT Therapeutics Announces $150 Million Private Placement Read More »
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-acting Anti-ige Antibody Portfolio News / By Karina Tin RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-acting Anti-ige Antibody Read More »
NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate Portfolio News / By Karina Tin NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate Read More »
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Portfolio News / By Karina Tin Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Read More »
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition Portfolio News / By Karina Tin Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition Read More »
Circle Pharma presents promising preclinical data on first-in-class oral macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024 Portfolio News / By Karina Tin December 9, 2024 Circle Pharma presents promising preclinical data on first-in-class oral macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024 Read More »
Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting Portfolio News / By Karina Tin December 9, 2024 Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting Read More »
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society Portfolio News / By Karina Tin December 6, 2024 Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society Read More »
